

2021 ACCP/ASHP BCOP Clinical Sessions

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education's Standards for Commercial Support and the Accreditation Council for Pharmacy Education's Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual or his or her spouse/partner has a financial relationship (e.g., employee, consultant, research grant recipient, speaker's bureau, or stockholder) in any amount occurring in the last 12 months with a commercial interest whose products or services may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ASHP education activities are qualified and selected by ASHP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual's participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

- Justin R. Arnall: Advisory Board and Speaker's Bureau – Novo Nordisk; Advisory Board (former) – CSL Behring
- Mitchell E. Hughes: Advisory Board – AstraZeneca, Genzyme, Janssen, AbbVie, Karyopharm; Young Investigator Research Grant – HOPA and Acerta Pharma
- Donald C. Moore: Advisory Board – Oncopeptides

All other planners, presenters, reviewers, ASHP and ACCP, and others with an opportunity to control content report no financial relationships relevant to this activity.